Rheumatology

Medicine & Life Sciences

1. Antibodies 7%
2. Antineutrophil Cytoplasmic Antibodies 11%
3. Antiphospholipid Antibodies 7%
4. Antirheumatic Agents 12%
5. Appointments and Schedules 5%
6. Arthritis 60%
7. Arthropathy, progressive pseudorheumatoid, of childhood 12%
8. Autoantibodies 7%
9. Autoimmune Diseases 5%
10. B-Lymphocytes 6%
11. Biological Products 16%
12. Biomarkers 5%
13. Child 25%
14. Chronic Kidney Failure 5%
15. Cohort Studies 14%
16. Connective Tissue Diseases 7%
17. Consensus 6%
18. Dendritic Cells 13%
19. Dermatomyositis 17%
20. Education 6%
21. Etanercept 9%
22. Glucocorticoids 8%
23. Granulomatosis with Polyangiitis 24%
24. Health Literacy 7%
25. Hospitalization 5%
26. Interferon Type I 16%
27. Interferons 7%
28. Interleukin-10 5%
29. Interviews 7%
30. Juvenile Arthritis 77%
31. Kidney 7%
32. Localized Scleroderma 8%
33. Lupus Nephritis 24%
34. Methotrexate 6%
35. Mi-2 antibodies 5%
36. Microscopic Polyangiitis 13%
37. Mitochondria 5%
38. Monocytes 6%
39. Muscles 5%
40. Myositis 14%
41. Natural History 6%
42. Nephritis 7%
43. Neutrophils 7%
44. Nucleic Acids 9%
45. Patient Acceptance of Health Care 9%
46. Patient Care Team 7%
47. Patient Participation 7%
48. Patient Reported Outcome Measures 7%
49. Pediatrics 48%
50. Population 6%
51. Poverty 10%
52. Psychology Transfer 7%
53. Recreation 8%
54. Registries 44%
55. Rheumatologists 18%
56. Rheumatology 100%
57. Sacroiliitis 13%
58. Safety-net Providers 11%
59. Social Determinants of Health 10%
60. Succinic Acid 7%
61. Systemic Lupus Erythematosus 86%
62. T-Lymphocytes 5%
63. Therapeutics 13%
64. Transition to Adult Care 25%
65. Translational Medical Research 8%
66. Uveitis 8%
67. Vasculitis 17%
68. Venous Thrombosis 6%
69. Young Adult 15%